
Halozyme Therapeutics, Inc.: shareholders and insiders
Price
$91.35
November 20, 2026Market cap $10.8B
What Ploutos Investor adds for Halozyme Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 26% since Nov 5, 2026, when the 10-Q these figures come from was filed ($122.96 then, $91.35 on Nov 20, 2026). The figures date from before that move.10-Q
Insiders and their shares
Purchases and sales by officers and directors from Nov 21, 2025 to Nov 18, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$50M
5 people
From Nov 21, 2025 to Nov 21, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan96%
- The rest4%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 21, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $49M by 5 people
- 2025: no buys, sold $1.2M by 2 people
- 2026: no buys, sold $49M by 5 people
- Nov 18, 2026Matthew L. PosardDirectorKind10b5-1
- Nov 18, 2026Matthew L. PosardDirectorKind10b5-1
- Nov 16, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Nov 16, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Nov 16, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Nov 16, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Nov 16, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Nov 16, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Nov 16, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Nov 13, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Nov 13, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Nov 13, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Nov 13, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Nov 12, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Nov 12, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Nov 12, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Oct 8, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Oct 8, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Oct 8, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Oct 8, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Oct 8, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Oct 7, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Oct 7, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Oct 7, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
- Oct 7, 2026Helen TorleyPRESIDENT AND CEOKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 18, 2026 | Matthew L. PosardDirector | 10b5-1 | 3,400 | $96.17 | $327.0K | Form 4 |
| Nov 18, 2026 | Matthew L. PosardDirector | 10b5-1 | 1,600 | $96.97 | $155.2K | Form 4 |
| Nov 16, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 20.0K | $16.65 | $333.0K | Form 4 |
| Nov 16, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 7,283 | $96.85 | $705.3K | Form 4 |
| Nov 16, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 4,802 | $97.96 | $470.4K | Form 4 |
| Nov 16, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 1,586 | $98.89 | $156.8K | Form 4 |
| Nov 16, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 4,897 | $100.10 | $490.2K | Form 4 |
| Nov 16, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 1,244 | $101.06 | $125.7K | Form 4 |
| Nov 16, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 188 | $101.72 | $19.1K | Form 4 |
| Nov 13, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 1,552 | $18.41 | $28.6K | Form 4 |
| Nov 13, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 18.4K | $16.65 | $307.2K | Form 4 |
| Nov 13, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 7,992 | $100.02 | $799.4K | Form 4 |
| Nov 13, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 12.0K | $100.61 | $1.2M | Form 4 |
| Nov 12, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 20.0K | $18.41 | $368.2K | Form 4 |
| Nov 12, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 10.7K | $101.09 | $1.1M | Form 4 |
| Nov 12, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 9,289 | $101.49 | $942.8K | Form 4 |
| Oct 8, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 20.0K | $18.41 | $368.2K | Form 4 |
| Oct 8, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 4,810 | $108.18 | $520.3K | Form 4 |
| Oct 8, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 3,090 | $108.91 | $336.5K | Form 4 |
| Oct 8, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 11.9K | $110.00 | $1.3M | Form 4 |
| Oct 8, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 200 | $110.51 | $22.1K | Form 4 |
| Oct 7, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 20.0K | $18.41 | $368.2K | Form 4 |
| Oct 7, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 8,600 | $111.03 | $954.9K | Form 4 |
| Oct 7, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 10.3K | $111.84 | $1.2M | Form 4 |
| Oct 7, 2026 | Helen TorleyPRESIDENT AND CEO | 10b5-1 | 900 | $112.78 | $101.5K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 2, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by HALO's officers and directors from 2006 up to November 20, 2025, 20 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 15 more, back to 2006
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- D.E. ShawIn the quarter+68%
- Bridgewater (Dalio)In the quarter-29%
- Renaissance TechnologiesIn the quarter+25%
- Citadel Advisors (Griffin)In the quarter+107%
- Millennium Mgmt (Englander)In the quarter+899%
- AQR CapitalIn the quarter-24%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| D.E. Shaw | 3.37M | +68% | $372M | 0.23% |
| Bridgewater (Dalio) | 328.3K | -29% | $36M | 0.16% |
| Renaissance Technologies | 598.1K | +25% | $66M | 0.09% |
| Citadel Advisors (Griffin) | 598.6K | +107% | $66M | 0.04% |
| Millennium Mgmt (Englander) | 198.3K | +899% | $22M | 0.02% |
| AQR Capital | 600.9K | -24% | $66M | 0.02% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 11.6% of its shares outstanding were held short, -10.7% since the report before.
- Shares held short
- 13.65M
- 11.6%
- Since the report before15.30M on Sep 30, 2026
- -10.7%
- 6.2
- 2.22M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 72%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 6.58M
- Nov 15, 2023: Shares held short 6.97M
- Nov 30, 2023: Shares held short 7.13M
- Dec 15, 2023: Shares held short 7.50M
- Dec 29, 2023: Shares held short 7.35M
- Jan 12, 2024: Shares held short 7.17M
- Jan 31, 2024: Shares held short 7.64M
- Feb 15, 2024: Shares held short 7.65M
- Feb 29, 2024: Shares held short 8.08M
- Mar 15, 2024: Shares held short 8.20M
- Mar 28, 2024: Shares held short 7.89M
- Apr 15, 2024: Shares held short 8.24M
- Apr 30, 2024: Shares held short 8.41M
- May 15, 2024: Shares held short 8.56M
- May 31, 2024: Shares held short 8.56M
- Jun 14, 2024: Shares held short 9.31M
- Jun 28, 2024: Shares held short 9.02M
- Jul 15, 2024: Shares held short 8.71M
- Jul 31, 2024: Shares held short 8.95M
- Aug 15, 2024: Shares held short 9.67M
- Aug 30, 2024: Shares held short 10.04M
- Sep 13, 2024: Shares held short 9.64M
- Sep 30, 2024: Shares held short 9.85M
- Oct 15, 2024: Shares held short 10.42M
- Oct 31, 2024: Shares held short 10.25M
- Nov 15, 2024: Shares held short 10.45M
- Nov 29, 2024: Shares held short 8.57M
- Dec 13, 2024: Shares held short 8.79M
- Dec 31, 2024: Shares held short 9.50M
- Jan 15, 2025: Shares held short 9.41M
- Jan 31, 2025: Shares held short 9.06M
- Feb 14, 2025: Shares held short 9.22M
- Feb 28, 2025: Shares held short 9.75M
- Mar 14, 2025: Shares held short 10.07M
- Mar 31, 2025: Shares held short 9.22M
- Apr 15, 2025: Shares held short 9.62M
- Apr 30, 2025: Shares held short 9.46M
- May 15, 2025: Shares held short 10.69M
- May 30, 2025: Shares held short 10.55M
- Jun 13, 2025: Shares held short 11.07M
- Jun 30, 2025: Shares held short 10.18M
- Jul 15, 2025: Shares held short 9.60M
- Jul 31, 2025: Shares held short 9.93M
- Aug 15, 2025: Shares held short 10.57M
- Aug 29, 2025: Shares held short 11.88M
- Sep 15, 2025: Shares held short 11.78M
- Sep 30, 2025: Shares held short 10.80M
- Oct 15, 2025: Shares held short 11.51M
- Oct 31, 2025: Shares held short 11.31M
- Nov 14, 2025: Shares held short 12.48M
- Nov 28, 2025: Shares held short 12.37M
- Dec 15, 2025: Shares held short 12.50M
- Dec 31, 2025: Shares held short 13.80M
- Jan 15, 2026: Shares held short 13.59M
- Jan 30, 2026: Shares held short 13.52M
- Feb 13, 2026: Shares held short 13.80M
- Feb 27, 2026: Shares held short 13.50M
- Mar 13, 2026: Shares held short 13.70M
- Mar 31, 2026: Shares held short 14.05M
- Apr 15, 2026: Shares held short 14.26M
- Apr 30, 2026: Shares held short 14.38M
- May 15, 2026: Shares held short 13.39M
- May 29, 2026: Shares held short 13.64M
- Jun 15, 2026: Shares held short 12.95M
- Jun 30, 2026: Shares held short 13.23M
- Jul 15, 2026: Shares held short 13.30M
- Jul 31, 2026: Shares held short 14.02M
- Aug 14, 2026: Shares held short 14.64M
- Aug 31, 2026: Shares held short 14.88M
- Sep 15, 2026: Shares held short 15.15M
- Sep 30, 2026: Shares held short 15.30M
- Oct 15, 2026: Shares held short 13.65M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading48.7% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 48.7% of the shares in the reported trades were short sales, against 60.1% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 48.7%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 60.1%
- Change
- -11.4 pts
- Short sales a dayon average, of 1.12M shares
- 546.9K
- More than atof 3,666 US-listed companies, same days
- 43%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 62.4%
- Oct 15, 2026: Short sales 62.8%
- Oct 16, 2026: Short sales 57.3%
- Oct 19, 2026: Short sales 73.1%
- Oct 20, 2026: Short sales 49.3%
- Oct 21, 2026: Short sales 74.5%
- Oct 22, 2026: Short sales 67.4%
- Oct 23, 2026: Short sales 52.2%
- Oct 26, 2026: Short sales 57.4%
- Oct 27, 2026: Short sales 51%
- Oct 28, 2026: Short sales 57%
- Oct 29, 2026: Short sales 63.1%
- Oct 30, 2026: Short sales 58%
- Nov 2, 2026: Short sales 48.3%
- Nov 3, 2026: Short sales 37.6%
- Nov 4, 2026: Short sales 53.8%
- Nov 5, 2026: Short sales 56%
- Nov 6, 2026: Short sales 53.4%
- Nov 9, 2026: Short sales 38.1%
- Nov 10, 2026: Short sales 63.3%
- Nov 11, 2026: Short sales 59.3%
- Nov 12, 2026: Short sales 61.3%
- Nov 13, 2026: Short sales 45.9%
- Nov 16, 2026: Short sales 40.1%
- Nov 17, 2026: Short sales 51.2%
- Nov 18, 2026: Short sales 57.5%
- Nov 19, 2026: Short sales 29.7%
- Nov 20, 2026: Short sales 46.1%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Helen TorleyPRESIDENT AND CEODirectly767.8K
- Michael J. LaBarreSVP, CHIEF TECHNICAL OFFICERDirectly173.8K
- Mark Howard SnyderSVP, CHIEF LEGAL OFFICERDirectly49.9K
- Matthew L. PosardDirectorDirectly48.6K
- Bernadette ConnaughtonDirectorDirectly40.4K
- Jeffrey William HendersonDirectorDirectly28.6K
- Nicole LaBrosseSVP, CHIEF FINANCIAL OFFICERDirectly22.1K
- Mahesh KrishnanDirectorDirectly14.5K
- Cortney CaudillSVP, CHIEF OPERATING OFFICERDirectly7,055
- David A RamsayEVP, PRESIDENT, DRUG DELIVERYDirectly4,592
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Helen TorleyPRESIDENT AND CEO | 767.8K | – | Nov 16, 2026 | Form 4 |
| Michael J. LaBarreSVP, CHIEF TECHNICAL OFFICER | 173.8K | – | Feb 27, 2025 | Form 4 |
| Mark Howard SnyderSVP, CHIEF LEGAL OFFICER | 49.9K | – | Jun 12, 2026 | Form 4 |
| Matthew L. PosardDirector | 48.6K | – | Nov 18, 2026 | Form 4 |
| Bernadette ConnaughtonDirector | 40.4K | – | Aug 10, 2026 | Form 4 |
| Jeffrey William HendersonDirector | 28.6K | – | Apr 28, 2025 | Form 4 |
| Nicole LaBrosseSVP, CHIEF FINANCIAL OFFICER | 22.1K | – | Sep 22, 2025 | Form 4 |
| Mahesh KrishnanDirector | 14.5K | – | Jun 29, 2026 | Form 4 |
| Cortney CaudillSVP, CHIEF OPERATING OFFICER | 7,055 | – | Mar 10, 2026 | Form 4 |
| David A RamsayEVP, PRESIDENT, DRUG DELIVERY | 4,592 | – | Jun 30, 2026 | Form 4 |
A lower bound: it counts only the 10 officers and directors with a market trade since Nov 22, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund1.03%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.80%
- IBBiShares Biotechnology ETFWeight in the fund0.72%
- IJKiShares S&P Mid-Cap 400 Growth ETFWeight in the fund0.49%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.27%
- VBKVanguard Small-Cap Growth Index FundWeight in the fund0.26%
- SPMDState Street(R) SPDR(R) Portfolio S&P 400(TM) Mid Cap ETFWeight in the fund0.26%
- IJHiShares Core S&P Mid-Cap ETFWeight in the fund0.26%
- MDYState Street SPDR S&P MidCap 400SM ETF TrustWeight in the fund0.25%
- IWPiShares Russell Mid-Cap Growth ETFWeight in the fund0.25%
38 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 604
- Q4 2025: Managers 620
- Q1 2026: Managers 639
- Q2 2026: Managers 669
Institutional investors by quarter
The fund managers holding HALO, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 669 managers held 124M shares, worth $9.7B. During the quarter 106 opened a position, 76 closed one, 265 added and 203 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter
- Vanguard Capital ManagementIn the quarter+1.5%
- Vanguard Portfolio ManagementIn the quarter+0.9%
- State StreetIn the quarter+4.9%
- InvescoIn the quarter-21%
- Morgan StanleyIn the quarter+11%
- Boston PartnersIn the quarter+3.3%
- Bank of AmericaIn the quarter-5.9%
- Geode Capital ManagementIn the quarter+0.6%
- William Blair Investment ManagementIn the quarter-0.6%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 13.27M | $1.0B | |
| Vanguard Capital Management | 5.35M | +1.5% | $419M |
| Vanguard Portfolio Management | 5.30M | +0.9% | $415M |
| State Street | 5.18M | +4.9% | $405M |
| Invesco | 3.18M | -21% | $249M |
| Morgan Stanley | 2.83M | +11% | $222M |
| Boston Partners | 2.77M | +3.3% | $217M |
| Bank of America | 2.74M | -5.9% | $215M |
| Geode Capital Management | 2.52M | +0.6% | $197M |
| William Blair Investment Management | 2.51M | -0.6% | $197M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Halozyme Therapeutics's filings show?
Who buys and sells is one part of Halozyme Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have HALO's insiders bought or sold?
From Jun 2, 2026 to Nov 18, 2026 Halozyme Therapeutics's insiders bought 0 and sold $33M of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold HALO?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $372M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.